ANI Pharmaceuticals Slides After Lowering FY26 Guidance for Cortrophin Gel Revenue

Dow Jones

Aug 07

Shares of ANI Pharmaceuticals slipped after the biopharmaceutical company cut its revenue guidance for Cortrophin Gel.

The stock was down 6%, to $77.70, late Friday morning, and has fallen 1.6% since the start of the year.

Chief Executive Nikhil Lalwani said the company lowered its full-year revenue guidance for Cortrophin Gel, a treatment for inflammatory certain inflammatory conditions, to between $520 million and $540 million from $540 million to $575 million.

Lalwani added that the company reaffirmed its full-year guidance of between $1.08 billion and $1.14 billion and adjusted earnings of $9.19 to $9.69 a share. Analysts polled by FactSet are expecting adjusted earnings per share of $9.45 on revenue of $1.12 billion.

For the second quarter, the company reported net income of $24.7 million, or $1.05 a share, compared with $8.5 million, or 36 cents a share, a year earlier.

Adjusted earnings per share were $2.21. Analysts polled by FactSet expected $2.04.

Revenue rose 26%, to $266 million. Analysts polled by FactSet expected $260.1 million. Net revenues from Cortrophin Gel was $117.1 million, up about 44%, in the second quarter.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2657343647"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2657343647\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2657343647?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 23:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657343647","market":"sg","top_or_hot":-1,"title":"ANI Pharmaceuticals Slides After Lowering FY26 Guidance for Cortrophin Gel Revenue","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ANI Pharmaceuticals slipped after the biopharmaceutical company cut its revenue guidance for Cortrophin Gel. \n</p>\n<p>\n  The stock was down 6%, to $77.70, late Friday morning, and has fallen 1.6% since the start of the year. \n</p>\n<p>\n  Chief Executive Nikhil Lalwani said the company lowered its full-year revenue guidance for Cortrophin Gel, a treatment for inflammatory certain inflammatory conditions, to between $520 million and $540 million from $540 million to $575 million. \n</p>\n<p>\n  Lalwani added that the company reaffirmed its full-year guidance of between $1.08 billion and $1.14 billion and adjusted earnings of $9.19 to $9.69 a share. Analysts polled by FactSet are expecting adjusted earnings per share of $9.45 on revenue of $1.12 billion. \n</p>\n<p>\n  For the second quarter, the company reported net income of $24.7 million, or $1.05 a share, compared with $8.5 million, or 36 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings per share were $2.21. Analysts polled by FactSet expected $2.04. \n</p>\n<p>\n  Revenue rose 26%, to $266 million. Analysts polled by FactSet expected $260.1 million. Net revenues from Cortrophin Gel was $117.1 million, up about 44%, in the second quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ANI Pharmaceuticals Slides After Lowering FY26 Guidance for Cortrophin Gel Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nANI Pharmaceuticals Slides After Lowering FY26 Guidance for Cortrophin Gel Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-08-07 23:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ANI Pharmaceuticals slipped after the biopharmaceutical company cut its revenue guidance for Cortrophin Gel. \n</p>\n<p>\n  The stock was down 6%, to $77.70, late Friday morning, and has fallen 1.6% since the start of the year. \n</p>\n<p>\n  Chief Executive Nikhil Lalwani said the company lowered its full-year revenue guidance for Cortrophin Gel, a treatment for inflammatory certain inflammatory conditions, to between $520 million and $540 million from $540 million to $575 million. \n</p>\n<p>\n  Lalwani added that the company reaffirmed its full-year guidance of between $1.08 billion and $1.14 billion and adjusted earnings of $9.19 to $9.69 a share. Analysts polled by FactSet are expecting adjusted earnings per share of $9.45 on revenue of $1.12 billion. \n</p>\n<p>\n  For the second quarter, the company reported net income of $24.7 million, or $1.05 a share, compared with $8.5 million, or 36 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings per share were $2.21. Analysts polled by FactSet expected $2.04. \n</p>\n<p>\n  Revenue rose 26%, to $266 million. Analysts polled by FactSet expected $260.1 million. Net revenues from Cortrophin Gel was $117.1 million, up about 44%, in the second quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANIP","symbol_name":"ANI Pharmaceuticals, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2657343647","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657343647","pubTimestamp":1786117080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of ANI Pharmaceuticals slipped after the biopharmaceutical company cut its revenue guidance for Cortrophin Gel.The stock was down 6%, to $77.70, late Friday morning, and has fallen 1.6% since the start of the year.Chief Executive Nikhil Lalwani said the company lowered its full-year revenue guidance for Cortrophin Gel, a treatment for inflammatory certain inflammatory conditions, to between $520 million and $540 million from $540 million to $575 million.Lalwani added that the company reaffirmed its full-year guidance of between $1.08 billion and $1.14 billion and adjusted earnings of $9.19 to $9.69 a share. Analysts polled by FactSet are expecting adjusted earnings per share of $9.45 on revenue of $1.12 billion.For the second quarter, the company reported net income of $24.7 million, or $1.05 a share, compared with $8.5 million, or 36 cents a share, a year earlier.Adjusted earnings per share were $2.21. Analysts polled by FactSet expected $2.04.Revenue rose 26%, to $266 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ANIP":"ANI Pharmaceuticals, Inc."},"translate_title":"ANI Pharmaceuticals 下调 26 财年 Cortrophin 凝胶收入指引后股价下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIP":1.5},"content_text":"Shares of ANI Pharmaceuticals slipped after the biopharmaceutical company cut its revenue guidance for Cortrophin Gel. \n\n\n  The stock was down 6%, to $77.70, late Friday morning, and has fallen 1.6% since the start of the year. \n\n\n  Chief Executive Nikhil Lalwani said the company lowered its full-year revenue guidance for Cortrophin Gel, a treatment for inflammatory certain inflammatory conditions, to between $520 million and $540 million from $540 million to $575 million. \n\n\n  Lalwani added that the company reaffirmed its full-year guidance of between $1.08 billion and $1.14 billion and adjusted earnings of $9.19 to $9.69 a share. Analysts polled by FactSet are expecting adjusted earnings per share of $9.45 on revenue of $1.12 billion. \n\n\n  For the second quarter, the company reported net income of $24.7 million, or $1.05 a share, compared with $8.5 million, or 36 cents a share, a year earlier. \n\n\n  Adjusted earnings per share were $2.21. Analysts polled by FactSet expected $2.04. \n\n\n  Revenue rose 26%, to $266 million. Analysts polled by FactSet expected $260.1 million. Net revenues from Cortrophin Gel was $117.1 million, up about 44%, in the second quarter.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}